{"entity":{"id":"adaptimmune","kind":"company","name":"Adaptimmune","aka":[],"tldr":"Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.","summary":"Adaptimmune, based in Abingdon and Philadelphia, developed Tecelra, or afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, and sold its US rights to US WorldMeds in 2025 amid financial distress. Afami-cel targets MAGE-A4 and was proved in SPEARHEAD-1 in synovial sarcoma, letetresgene autoleucel targets NY-ESO-1, and uza-cel, its PRAME programme, was sold. OnCo links it to sarcomas, to the afami-cel drug record and to the SPEARHEAD-1 papers. Whether a scientifically successful cell therapy can survive commercially in a rare cancer is the question its history answers, and the answer here was no. Afamitresgene autoleucel has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.adaptimmune.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["afamitresgene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Abingdon / Philadelphia","country":"GB","companyType":"cell-therapy","website":"https://www.adaptimmune.com","investors":[],"funding":[]},"route":"/companies/adaptimmune/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"drug":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}],"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"trial":[{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/"}],"paper":[{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/"}]}}